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STRUCTURED SUMMARY 
Background & Aims 
Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are commonly used. PPIs 
have been shown to promote liver cancer in rats; however, only one study has examined the association 
in humans. We investigated PPIs and H2RAs and risk of primary liver cancer in two large independent 
study populations. 
Methods 
We conducted a nested case-control study within the Primary Care Clinical Informatics Unit (PCCIU) 
database in which up to five controls were matched to cases with primary liver cancer, recorded by 
General Practitioners. Odds ratios (ORs) and 95% confidence intervals (95% CIs) for associations with 
prescribed PPIs and H2RAs were calculated using conditional logistic regression. We also conducted a 
prospective cohort study within the UK Biobank using self-reported medication use and cancer-registry 
recorded primary liver cancer. Hazard ratios (HRs) and 95% CIs were calculated using Cox regression. 
Results 
In the PCCIU case-control analysis, 434 liver cancer cases were matched to 2,103 controls. In the UK 
Biobank cohort, 182 out of 475,768 participants developed liver cancer. In both, ever use of PPIs was 
associated with increased liver cancer risk (adjusted OR 1.80, 95% CI 1.34, 2.41 and adjusted HR 1.99, 
95% CI 1.34, 2.94, respectively). There was little evidence of association with H2RA use (adjusted OR 
1.21, 95% CI 0.84, 1.76 and adjusted HR 1.70, 95% CI 0.82, 3.53, respectively).  
Conclusion 
We found some evidence that PPI use was associated with liver cancer. Whether this association is 
causal or reflects residual confounding or reverse causation requires additional research.  
 
Keywords: proton pump inhibitors, histamine-2 receptor antagonists, hepatocellular carcinoma, 
intrahepatic bile duct carcinoma, cohort, case-control. 
 
  
INTRODUCTION 
Primary liver cancer is the fifth most common cancer in men and ninth in women in the world1. 
Recently the incidence and mortality from liver cancer has increased markedly both in the UK2 and 
US3. The low estimates of five year relative survival of 15% in the US4, and 8% in the UK5, highlight 
the importance of preventing liver cancer. 
 
Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely prescribed 
medications, used primarily for the treatment of peptic ulcers, dyspepsia, and gastro-oesophageal reflux 
disease (GORD).  Despite their widespread use, there have been concerns about potential adverse 
effects of PPIs6,7 and H2RAs8 potentially caused by a range of mechanisms including the reduced 
absorption of nutrients9 , hypergastrinemia10 and the overgrowth of bacteria (due to lower stomach acid 
levels)8,11. Many studies have investigated the effect of PPIs and H2RAs on the stomach12,13, and 
particularly on gastric cancer risk14,15.  Recently additional concerns have been raised about the effects 
that PPIs and H2RAs have upon the liver. A recent animal study found that PPIs promote progression of 
alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis in mice16 due 
to an overgrowth of bacteria. Likewise, in another animal study, PPI use was shown to promote liver 
tumors in rats17. 
 
Despite these findings, only one previous observational study has examined the association between PPI 
and H2RA use and the risk of primary liver cancer in humans18. That case-control study, which only 
investigated hepatocellular carcinoma (HCC), and not intrahepatic bile duct carcinoma (IBDC), 
observed a marked increase in risk of HCC with H2RA use but not PPI use. We therefore examined the 
association between use of PPIs and H2RAs and the risk of primary liver cancer using data from two 
independent UK datasets. 
 
MATERIALS and METHODS 
Primary Care Clinical Informatics Unit (PCCIU) 
 
Data source 
The Primary Care Clinical Informatics Unit (PCCIU) database is an electronic primary care dataset 
from Scotland that captures approximately 15% of the Scottish population19. The PCCIU contains 
computerized medical records containing data from 1993 and 2011 capturing approximately 15% of the 
Scottish general practice population. The PCCIU contains demographics and details of patient 
encounters, clinical diagnosis, and prescriptions. Data access was approved by the Research 
Applications and Data Management Team of the University of Aberdeen, and we obtained ethics 
approval for this analysis from the School of Medicine, Dentistry and Biomedical Sciences Research 
Ethics Committee at Queen’s University Belfast (reference number: 15.43) 
 
Study design 
We conducted a nested case-control study within PCCIU. Cases had a first diagnosis of primary liver 
cancer, including HCC and IBDC, (based upon GP Read code: B15, excluding B153) between January 
1, 1999 and April 30, 2011. Up to five controls were matched to each case on exact year of birth, sex 
and General Practitioners (GP) practice. The index date for the cases was defined as the date of 
diagnosis of primary liver cancer and cases had to be free from cancer (excluding non-melanoma skin 
cancer) prior to this date. The index date for the controls was the diagnosis date of their matched case, 
controls were free from any cancer (apart from non-melanoma skin cancer) prior to the index date. 
 
The start of prescription records was considered January 1, 1996 (as prescriptions prior to this date were 
less likely to have been electronically recorded) or the date of patient registration at a GP practice if this 
occurred after January 1, 1996. The shortest duration of available prescription records was determined 
within each matched set of a case and controls.  The start of the exposure period was then set as the 
index date minus this duration within each matched set of a case and controls to ensure all members of 
the matched set had an identical length of exposure period. The end of the exposure period was one year 
prior to the index date to reduce the potential for reverse causation due to increased exposure to 
healthcare professionals following cancer symptoms.  Cases and controls with less than three years of 
prescription records prior to their index date were excluded. 
 
Exposure 
Medication use was determined from GP prescriptions in the exposure period. For each case and 
control, we extracted prescriptions for PPIs20 (including esomeprazole, lansoprazole, omeprazole, 
pantoprazole, rabeprazole sodium) and H2RAs20 (including cimetidine, famotidine, nizatidine, 
ranitidine). A quantity of 56 tablets was assumed for the less than 0.1% of prescriptions where the 
quantity recorded in the PCCIU database was assumed incorrect, based upon the most common PPI 
prescription size. Defined daily doses (DDD) were calculated from the quantity of tablets and strength, 
as defined by World Health Organization21. 
 
Covariates 
Comorbidities were obtained from GP diagnosis codes prior to the index date, including diabetes, 
coronary heart disease, myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular 
disease, cerebrovascular accident, chronic obstructive pulmonary disease, mental illness, gastro-
oesophageal reflux disease, peptic ulcer disease, and liver diseases (hepatitis, cirrhosis, alcoholic fatty 
liver, non-alcoholic fatty liver, biliary cirrhosis). Statins and aspirin use were identified from 
prescription records. Lifestyle risk factors were extracted from GP records including smoking status 
(never smoker, previous smoker, and current smoker), alcohol status (none, low [e.g. moderate or light 
drinker], or high intake [e.g. above recommended limits, chronic alcoholism]), and obesity ([BMI>30], 
or not obese) using the most recent record prior to the index date. Postcode of the GP practice was used 
to assign deprivation fifths using the Scottish Index of Multiple Deprivation22. 
 
UK Biobank 
Data source 
The UK Biobank contains approximately 500,000 volunteer participants aged 40 to 69 from England, 
Scotland and Wales recruited from 2006 to 201023.  A wide range of data was collected including 
lifestyle, environment, medical history and physical measures, along with biological samples. The UK 
Biobank is linked to cancer registry data from the Health and Social Care Information Centre (in 
England and Wales) and the National Health Service Central Register (in Scotland). The UK Biobank 
has ethical approval from the North West Multi-Centre Research Ethics Committee.  All participants 
provided written informed consent. 
 
Study design 
We conducted a prospective cohort study among participants in the UK Biobank. Liver cancer patients 
were identified using cancer registry records (based upon ICD 10 codes C22, liver and intrahepatic bile 
duct cancer) up to September 30, 2014.  Participants with a cancer diagnosis (apart from non-melanoma 
skin cancer) prior to baseline or in the year after baseline were excluded (as these cancers may have 
been present at baseline). Consequently, cohort participants were followed from one year after baseline 
until the date of liver cancer diagnosis or censoring (on the earliest of the date of death, date of other 
cancer, or September 30, 2014).  
 
Exposure 
Self-reported PPI and H2RA use was first ascertained from participants using a touchscreen 
questionnaire at baseline, and then verified during verbal interview with a UK Biobank nurse. 
 
Covariates 
Covariates were determined from patient interview and touch screen at baseline. These included age, 
gender, comorbidities (gastro-oesophageal reflux disease, peptic ulcer disease, cirrhosis, hepatitis, and 
diabetes) and other medication use (statins and aspirin). Lifestyle risk factors including smoking (never 
smoker, previous smoker or current smoker) and alcohol consumption (never, <1 day per week, 1-2 
days per week, 3-4 days per week or >4 days per week) were also ascertained. BMI (categorized as 
under or normal weight [<25], overweight [25-30], obese [>30]) was calculated from height and weight 
measurements recorded at baseline by trained research staff. The Townsend score based upon postcode 
of residence was determined as a measure of deprivation24. 
 
Statistical analysis 
The characteristics of cases and control were compared using descriptive statistics (for continuous 
variables) or frequencies and percentages (for categorical variables).  
 
In PCCIU, we used conditional logistic regression to estimate odd ratios (OR) and 95% confidence 
intervals (95% CI) for the association between PPI/H2RA use and liver cancer risk. The matched design 
accounted for age, sex and GP practice, and adjustments were made for comorbidities (as described), 
obesity, aspirin and statins use. A separate complete case analysis was conducted additionally adjusted 
for smoking and alcohol.  
 
Analyses were repeated by number of prescriptions, by DDDs and by type of PPIs. Similar analyses 
were conducted for H2RA use. A sensitivity analysis was conducted adjusting for H2RAs and PPIs 
simultaneously. Additional sensitivity analyses were conducted removing prescriptions in the 2 years 
prior to index date (including only patients with 4 years of medical records), and in the 4 years prior to 
index date (including only patients with 6 years of medical records), to investigate the potential for 
reverse causation potentially due to gastrointestinal symptoms. A further sensitivity analysis was 
conducted adjusting for smoking and alcohol using multiple imputation with chained equations25. First, 
an imputation model was created using ordered logit models including age, gender, PPI, H2RA, obesity, 
comorbidity, statins and aspirin use, separately for cases and controls. Twenty-five imputations were 
conducted and results were combined using Rubin’s rules26. 
 
The UK Biobank cohort was analysed using Cox regression with age as the underlying time scale 
(individuals were considered at risk from birth and under observation from age at baseline, left 
truncated) to calculate hazard ratios (HR) and 95% CIs for PPI/H2RA use and liver cancer risk and by 
histological types (HCC based upon ICD 10 code C22.0 and IBDC code C22.1). In adjusted analyses 
the model contained age, gender, deprivation, BMI, alcohol, smoking, comorbidities at baseline 
(GORD, peptic ulcer disease, cirrhosis, hepatitis and diabetes) and statins and aspirin use at baseline. 
Sensitivity analyses were conducted adjusting for H2RAs and PPIs simultaneously and by repeating the 
analyses starting follow-up at 2 years and 4 years after baseline (to remove cancers within 2 and 4 years, 
respectively, which could have influenced medication prescribing at baseline).   
  
RESULTS 
 
PCCIU 
Our nested case-control study in PCCIU included 434 cases of liver cancer and 2,103 matched controls 
(Table 1). The median exposure period was 5.5 years (min 2.0, max 13.3) in cases and controls. Liver 
cancer cases were more likely than controls to smoke, consume high levels of alcohol, use aspirin, and 
have diabetes, liver diseases and peptic ulcer. 
 
Overall, a greater proportion of liver cancer cases used PPIs compared with controls (33% vs 23%) 
(Table 2). PPI use was associated with increased risk of liver cancer (unadjusted OR 1.74, 95% CI 1.38, 
2.19; fully adjusted OR 1.80, 95% CI 1.34, 2.41). However, we found no evidence of a dose response 
relationship with increased duration of exposure (1-11 PPI prescriptions fully adjusted OR =1.92, 95% 
CI 1.33, 2.69 and 12 or more prescriptions OR =1.66, 95% CI 1.13, 2.45). Associations were similar 
when exposure was based upon DDDs. There were stronger associations for omeprazole (fully adjusted 
OR 1.83, 95% CI 1.30, 2.56) than lansoprazole (fully adjusted OR 1.34, 95% CI 0.93, 1.93). 
We found no association between H2RA use and risk of liver cancer (ever H2RA use: fully adjusted OR 
1.21, 95% CI 0.84, 1.76), regardless of duration of use and type (Table 2).  
 
 In sensitivity analyses (Table 3), the association with PPI use was moderately attenuated after 
introducing 2 year (fully adjusted OR 1.65, 95% CI 1.15, 2.35) and 4 year lags (fully adjusted OR 1.60, 
95% CI 0.97, 2.64). Associations were similar in other sensitivity analyses. 
 
 
UK Biobank 
Among 471,851 participants in the UK Biobank, we identified 182 liver cancer cases over a median 
follow-up of 5.6 years (range 1.0-8.6 years). Liver cancer cases were more likely than controls to be 
older, male, from deprived areas, smoke, consume alcohol more often, be overweight or obese, have 
diabetes, cirrhosis, hepatitis, and use statins and aspirin (Table 1). 
 
Ever use of PPIs was associated with 2-fold increased risk of liver cancer (unadjusted HR 2.08, 95% CI 
1.46, 2.96; fully adjusted HR 1.99, 95% CI 1.34, 2.94). The magnitude of the association with PPI use 
was greater for risk of IBDC (adjusted HR 3.12, 95% CI 1.72, 5.68) than for risk of HCC (adjusted HR 
1.60, 95% CI 0.91, 2.83). The associations were similar by type of PPIs. A similar, though not 
statistically significant, association was observed between H2RAs and liver cancer risk (adjusted HR 
1.70; 95% CI 0.82, 3.53).  
 
Sensitivity analyses (Table 5) revealed the association between PPI use and liver cancer was slightly 
attenuated after introducing a 2 year lag (adjusted HR 1.79, 95% CI 1.15, 2.77) and more attenuated 
when a 4 year lag was introduced (adjusted HR 1.30, 95% CI 0.66, 2.55). This pattern was similar for 
HCC and IBDC.  
 
  
DISCUSSION 
 
Using data from two large population-based studies which differed in design (case-control versus 
prospective cohort) and method of exposure ascertainment (self-report versus prescription records), we 
found a consistent association between PPI use and liver cancer risk. Conversely, there was little 
evidence of association with use of H2RAs. PPI use was more strongly associated with the risk of IBDC 
than for HCC, and the association was not attenuated after adjustments for available confounders.  
However the associations were slightly attenuated when controlling for potential reverse causation 
(using lags) and, using data from PCCIU, we found no evidence of a dose response based upon duration 
of use.   
 
A previous case-control study in Taiwan18 found a statistically significant association between use of 
H2RAs and the risk of HCC (adjusted OR 1.46 95% CI 1.30, 1.64) but not PPIs (adjusted OR 0.94, 95% 
CI 0.78, 1.13), but did not investigate IBDC. Although we observed stronger associations between PPIs 
and liver cancer risk, in analyses by subtype these associations were only apparent for IBDC. The 
difference in the findings of our study and the Taiwan study are unclear but could reflect differences in 
the underlying populations with respect to other liver cancer risk factors or genetic factors, differences 
in PPI prescribing patterns, or study specific differences (for instance they frequency matched controls 
to cases whereas we individually matched). 
 
Our study has a number of strengths. We observed consistent findings for PPIs and liver cancer risk 
across two independent datasets. There was minimal risk of recall bias as PCCIU analyses were based 
upon GP prescription records whilst UK Biobank was a prospective cohort study in which medications 
were recorded at least one year prior to liver cancer onset. In both datasets we adjusted for a wide range 
of confounders and, particularly, in UK Biobank we had detailed information on lifestyle risk factors 
including smoking and alcohol.  Also, data on number of prescriptions were available in PCCIU. 
 
The main limitation is that we cannot rule out confounding by incomplete or unknown exposures. 
Although we adjusted for cirrhosis and liver disease, cirrhosis patients are commonly prescribed PPIs27 
and therefore any misclassification within PCCIU or UK Biobank could lead to residual confounding. 
Furthermore we cannot rule out confounding by indication28, for example, individuals with gastro-
oesophageal reflux disease, for which they receive PPIs, have been shown to have increased risk of 
nonalcoholic fatty liver disease29 which is a risk factor for primary liver cancer. There was an indication 
of reverse causation as the associations were slightly attenuated when medication use in the period prior 
to onset was removed, which could be influenced by liver cancer symptoms. A further weakness was 
that histological subtype was not available in PCCIU but we did have these data in UK Biobank.  
Finally, adherence to medications was unknown in either dataset, but this seems more likely to dilute 
associations.   
 
The cause of the observed increased risk of liver cancer with PPIs use is unknown. If real, our findings 
are consistent with an experimental study which showed that PPIs can promote liver tumors in rats17.  
Various potentially harmful mechanisms of PPIs have been proposed9. In particular, long term PPIs use 
can lead to hypergastrinemia which has been shown to have a carcinogenic effect30 , particularly on liver 
cells31 . Also PPIs reduce gastric acid secretion increasing the survival of various microbes in the 
stomach7,32. The resulting bacterial overgrowth could greatly contribute to the transformation of primary 
bile acid in the intestine to secondary bile acid33 and has been shown to impact upon the liver34 
exacerbating various liver diseases in mice16. A high level of secondary bile acid has been shown to 
cause toxic, inflammatory, and DNA damaging effects on liver cells and bile duct cells, leading to 
HCC35 and cholangiocarcinoma36. The generally weaker associations observed for H2RAs could reflect 
the weaker acid suppression and the less marked effect on gastrin associated with these medications10. 
Alternatively, various features of the observed association do not support a causal interpretation 
including the lack of dose response (the most marked association was seen for less than 6 prescriptions), 
the possibility of confounding by indication, and the possibility of reverse causation (suggested by the 
attenuation of associations when prescriptions in the period prior to diagnosis where removed). 
However, the widespread use of PPIs, and particularly their use without clear indication37, and the high 
mortality of liver cancer highlight the need for further research. Specifically, further studies should 
contain sufficiently long follow-up to investigate reverse causation, high quality liver cancer outcome 
data and detailed and complete information on liver cancer risk factors.   
 
In conclusion, our study provides some evidence of an association between PPI use and the risk of liver 
cancer; however, this association requires confirmation in other studies due to the possibility of residual 
confounding and/or reverse causation.   
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Table1: Characteristics of liver cancer cases and controls in Primary Care Clinical Informatics Unit and UK Biobank 
 Primary Care Clinical 
Informatics Unit 
UK Biobank 
Cases Controls Cases Controls 
Count 434 (17.1%) 2,103 (82.9%) 182 471669 
Median exposure years  
(min, max) 
5.47  
(2.00, 13.31) 
5.45  
(2.00, 13.31) 
  
Year of diagnosis: 1996-1999 10 (2.3%)    
                            2000-2003 82 (18.9%)    
                            2004-2007 237 (54.6%)    
                            2008-2011 105 (24.1%)  67 (36.8%)  
                            2012-2015   115 (63.2%)  
     
Age at index†/baseline†:0-49 12 (2.8%) 61 (2.9%) 6 (3.3%) 114821 (24.3%) 
                                   50-59 62 (14.3%) 316 (15.0%) 59 (32.4%) 158665 (33.6%) 
                                   60-69 139 (32.0%) 693 (32.9%) 114 (62.6%) 196054 (41.6%) 
                                   70-79 143 (32.9%) 693 (32.9%) 3 (1.6%) 2129 (0.5%) 
                                   80+ 78 (17.9%) 340 (16.2%)   
     
Male 292 (67.3%) 1412 (67.1%) 114 (62.6%) 217239 (46.1%) 
     
Deprivation:  1 (Least deprived) 70 (16.1%) 340 (16.2%) 27 (14.8%) 94450 (20.0%) 
                       2 61 (14.0%) 294 (14.0%) 35 (19.2%) 94030 (19.9%) 
                       3 84 (19.4%) 413 (19.4%) 41 (22.5%) 93947 (19.9%) 
                       4 105 (24.2%) 501 (23.8%) 40 (22.0%) 94411 (20.0%) 
                       5 (Most deprived) 107 (24.6%) 521 (24.7%) 39 (21.4%) 94234 (20.0%) 
                       Missing 7 (1.6%) 34 (1.6%) 0 (0.0%) 597 (0.1%) 
     
Smoking status§: Never 135 (31.1%) 806 (38.3%) 65 (35.7%) 258073 (54.7%) 
                        Previous 130 (30.0%) 578 (27.5%) 87 (47.8%) 160827 (34.1%) 
                        Current  116 (26.7%) 428 (20.4%) 30 (16.5%) 50023 (10.6%) 
                        Missing 53 (12.2%) 291 (13.8%) 0 (0.0%) 2746 (0.6%) 
     
Comorbidities: GORD <5 (<1.1%) 17 (0.8%) 6 (3.3%) 19596 (4.2%) 
                          Cirrhosis   13 (7.1%) 466 (0.1%) 
                          Hepatitis   16 (8.8%) 2367 (0.5%) 
                          Liver diseases‡  34 (7.8%) 11 (0.5%)   
                          Diabetes 53 (12.2%) 89 (4.2%) 35 (19.2%) 23812 (5.0%) 
                          Peptic ulcer 13 (3.0%) 24 (1.1%) <5 (<2.7%) 5729 (1.2%) 
     
Other drug use: Statins 112(25.8%) 572(27.2%) 45 (24.7%) 76505 (16.2%) 
                           Aspirin 158 (36.4%) 659(31.3%) 43 (23.6%) 64755 (13.7%) 
     
BMI: Normal\under weight   47 (25.8%) 154943 (32.8%) 
          Overweight   71 (39.0%) 199281 (42.3%) 
          Obese 102 (23.5%) 423 (20.1%) 64 (35.2%) 114531 (24.3%) 
          Missing\not obese 332 (76.5%) 1680 (79.9%)   
          Missing   0 (0.0%) 2914 (0.6%) 
     
Alcohol consumption§     
Never 91 (21.0%) 346 (16.4%) 30 (16.5%) 37871 (8.0%) 
< 1 day per week   40 (22.0%) 106526 (22.6%) 
1-2 days per week   34 (18.7%) 121501 (25.8%) 
3-4 days per week   36 (19.8%) 108918 (23.1%) 
>4 days per week   42 (23.1%) 95422 (20.2%) 
Low 189 (43.5%) 1104 (52.5%)   
High 53 (12.2%) 93 (4.4%)   
Missing 101 (23.3%) 560 (26.7%) 0 (0.0%) 1431 (0.3%) 
†Age at index date in Primary Care Clinical Informatics Unit data and age at baseline in UK Biobank data. 
‡ Liver diseases includes cirrhosis, alcoholic and non-alcoholic fatty liver, and hepatitis. 
§ Alcohol and smoking consumption based upon Read codes in Primary Care Clinical Informatics Unit data and 
questionnaire data in UK Biobank. 
 
 
Table 2. The association between PPI and H2RA use and risk of liver cancer in Primary Care Clinical Informatics Unit. 
 Cases 
n (%) 
Controls 
n (%) 
Unadjusted  Adjusted†  Fully adjusted‡ 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
  n=2536  n=2536  n= 1533  
Any PPIs        
Never 289 (66.6%) 1618 (76.9%) 1.00 (ref. cat.)  1.00 (ref. cat.)  1.00 (ref. cat.)  
Ever 145 (33.4%) 485 (23.1%) 1.74 (1.38,2.19) <0.001 1.65 (1.28,2.12) <0.001 1.80 (1.34,2.41) <0.001 
         
1-11 prescriptions 77 (17.7%) 259 (12.3%) 1.74 (1.30,2.32) <0.001 1.69 (1.24,2.30) 0.001 1.92 (1.33,2.69) <0.001 
12+ prescriptions 68 (15.7%) 226 (10.8%) 1.73 (1.28,2.35) <0.001 1.60 (1.15,2.23) 0.005 1.66 (1.13,2.45) 0.01 
         
1-6 prescriptions 63 (14.5%) 214 (10.2%) 1.70 (1.25,2.33) 0.001 1.71 (1.22,2.38) 0.002 1.98 (1.35,2.89) <0.001 
7-12 prescriptions 16 (3.7%) 52 (2.5%) 1.83 (1.02,3.26) 0.041 1.61 (0.87,2.99) 0.13 1.58 (0.77,3.25) 0.213 
13-36 prescriptions 49 (11.3%) 153 (7.3%) 1.81 (1.28,2.56) 0.001 1.65 (1.14,2.40) 0.008 1.68 (1.07,2.61) 0.022 
37+ prescriptions 17 (3.9%) 66 (3.1%) 1.54 (0.87,2.72) 0.141 1.40 (0.75,2.60) 0.285 1.72 (0.87,3.38) 0.115 
         
1-183 DDDs 59 (13.6%) 198 (9.4%) 1.74 (1.26,2.40) 0.001 1.77 (1.26,2.49) 0.001 2.06 (1.36,3.00) <0.001 
184-365 DDDs 16 (3.7%) 52 (2.5%) 1.76 (0.99,3.10) 0.053 1.53 (0.83,2.86) 0.178 1.70 (0.84,3.59) 0.145 
366 - 1095 DDDs 38 (8.8%) 138 (6.6%) 1.60 (1.09,2.35) 0.017 1.46 (0.97,2.20) 0.072 1.34 (0.80,2.18) 0.245 
1096 DDDs+ 32 (7.4%) 97 (4.6%) 1.95 (1.26,3.01) 0.003 1.75 (1.09,2.82) 0.02 2.04 (1.23,3.66) 0.01 
         
PPIs by type:        
Omeprazole (user v non-user) 93 (21.4%) 305 (14.5%) 1.68 (1.28,2.20) <0.001 1.61 (1.20,2.16) 0.001 1.83 (1.30,2.56) <0.001 
Lansoprazole (user v non-user) 71 (16.4%) 256 (12.2%) 1.41 (1.05,1.89) 0.022 1.31 (0.96,1.80) 0.089 1.34 (0.93,1.93) 0.117 
         
         
Any H2RAs         
Never 371 (85.5%) 1851 (88.1%) 1.00 (ref. cat.)  1.00 (ref. cat.)  1.00 (ref. cat.)  
Ever 63 (14.5%) 252 (11.9%) 1.23 (0.91,1.66) 0.177 1.19 (0.87,1.64) 0.274 1.21 (0.84,1.76) 0.31 
         
1-11 prescriptions 34 (7.8%) 161 (7.7%) 1.04 (0.70,1.54) 0.84 1.04 (0.69,1.57) 0.840 1.22 (0.75,1.96) 0.418 
12+ prescriptions 29 (6.7%) 91 (4.3%) 1.56 (1.01,2.40) 0.044 1.45 (0.92,2.29) 0.113 1.22 (0.70,2.07) 0.496 
         
1-6 prescriptions 27 (6.2%) 129 (6.1%) 1.03 (0.66,1.58) 0.907 1.06 (0.67,1.65) 0.830 1.25 (0.70,2.03) 0.406 
7-12 prescriptions 7 (1.6%) 32 (1.5%) 1.10 (0.48,2.50) 0.821 1.00 (0.43,2.37) 0.988 1.10 (0.42,2.93) 0.845 
13-36 prescriptions 20(4.6%) 61 (2.9%) 1.60 (0.95,2.68) 0.078 1.54 (0.90,2.65) 0.112 1.46 (0.79,2.72) 0.235 
37+ prescriptions 9 (2.1%) 30 (1.4%) 1.49 (0.70,3.15) 0.295 1.24 (0.54,2.83) 0.604 0.75 (0.26,2.09) 0.580 
         
1-183 DDDs 26 (6.0%) 124 (5.9%) 1.03 (0.66,1.60) 0.887 1.07 (0.68,1.70) 0.761 1.24 (0.73,2.12) 0.429 
184-365 DDDs 8 (1.8%) 28 (1.3%) 1.39 (0.52,3.09) 0.415 1.19 (0.52,2.72) 0.682 1.47 (0.56,3.86) 0.437 
366 - 1095 DDDs 20 (4.6%) 64 (3.0%) 1.52 (0.91,2.54) 0.111 1.50 (0.88,2.55) 0.137 1.33 (0.71,2.50) 0.374 
1096 DDDs+ 9 (2.1%) 36 (1.7%) 1.25 (0.60,2.62) 0.546 1.03 (0.46,2.30) 0.934 0.79 (0.30,2.07) 0.629 
         
H2RAs by type:         
Cimetidine (user v non-user) 19 (4.4%) 92 (4.4%) 0.94 (0.56,1.57) 0.801 0.85 (0.49,1.47) 0.564 0.97 (0.50,1.88) 0.923 
Ranitidine (user v non-user) 45 (10.4%) 166 (7.9%) 1.35 (0.95,1.90) 0.097 1.38 (0.96,1.99) 0.083 1.41 (0.91,2.15) 0.110 
†Study matched on age, gender and general practice and model contains obesity, comorbidities in exposure period (including diabetes, coronary heart disease, 
myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, cerebrovascular accident, chronic obstructive pulmonary disease, mental 
illness, liver disease, peptic ulcer disease) and other medication use in exposure period (statins, aspirin) 
‡ Same model as † but alcohol and smoking added 
Table 3. Sensitivity analysis for the association between PPI and H2RA use and risk of liver cancer in Primary Care Clinical Informatics Unit. 
 Cases 
n/N (%) 
Controls 
n/N (%) 
Unadjusted  Adjusted†  Fully adjusted‡ 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
PPIs (user versus non-user)        
 Main analysis 145/434 (33.4%) 485/2103 (23.1%) 1.74 (1.38,2.19)) <0.001 1.65 (1.28,2.12) <0.001 1.80 (1.34,2.41) <0.001 
 Removing prescriptions 2 years before index 92/336 (27.4%) 320/1631 (19.6%) 1.59 (1.20,2.10) 0.001 1.50 (1.10,2.05) 0.010 1.65 (1.15,2.35) 0.006 
 Removing prescriptions 4 years before index 40/205 (19.5%) 149/988 (15.1%) 1.38 (0.92,2.06) 0.120 1.30 (0.83,2.02) 0.252 1.60 (0.97,2.64) 0.065 
 Lifestyle factors adjusted for using MI§ 145/434 (33.4%) 485/2103 (23.1%) 1.74 (1.38,2.19) <0.001 1.65 (1.28,2.12) <0.001 1.67 (1.29,2.15) <0.001 
 Ever use >= 3 prescriptions 104/434 (24.0%) 340/2103 (16.2%) 1.67 (1.29,2.16) <0.001 1.57 (1.18,2.07) 0.002 1.61 (1.16,2.22) 0.004 
 Additionally adjusting for H2RAs¶ 145/434 (33.4%) 485/2103 (23.1%) 1.74 (1.38,2.19)) <0.001 1.64 (1.27,2.12) <0.001 1.79 (1.33,2.40) <0.001 
         
         
H2RAs (user versus non-user)        
 Main analysis 63/434 (14.5%) 252/2103 (11.9%) 1.23 (0.91,1.66) 0.177 1.19 (0.87,1.64) 0.274 1.21 (0.84,1.76) 0.310 
 Removing prescriptions 2 years before index 51/336 (15.2%) 205/1631 (12.6%) 1.22 (0.88,1.70) 0.248 1.20 (0.84,1.71) 0.323 1.14 (0.75,1.74) 0.525 
 Removing prescriptions 4 years before index 29/205 (14.1%) 112/988 (11.3%) 1.24 (0.79,1.93) 0.352 1.20 (0.74,1.93) 0.464 1.03 (0.60,1.78) 0.907 
 Lifestyle factors adjusted for using MI§ 63/434 (14.5%) 252/2103 (11.9%) 1.23 (0.91,1.66) 0.177 1.19 (0.87,1.64) 0.274 1.22 (0.89,1.69) 0.215 
 Ever use >= 3 prescriptions 48/434 (11.1%) 158/2103 (7.5%) 1.49 (1.05,2.10) 0.023 1.43 (1.00,2.06) 0.051 1.38 (0.90,2.12) 0.136 
 Additionally adjusting for PPIs¶ 145/434 (33.4%) 485/2103 (23.1%) 1.74 (1.38,2.19)) <0.001 1.05 (0.76,1.46) 0.774 1.06 (0.72,1.55) 0.776 
         
†Study matched on age, gender and general practice and model contains obesity, comorbidities in exposure period (including diabetes, coronary heart disease, 
myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, cerebrovascular accident, chronic obstructive pulmonary disease, mental 
illness, liver disease, peptic ulcer disease) and other medication use in exposure period (statins, aspirin) 
‡ Same model as † but alcohol and smoking added. 
§Using multiple imputation to adjust for alcohol and smoking. 
¶Model same as † and ‡ but additionally contains H2RAs and PPIs. 
  
 Table 4. The association between PPI and H2RA use and risk of liver cancer in UK Biobank. 
 
Users  Non-users  Unadjusted   Adjusted† 
Cases P-years Cases P-years HR (95% CI) P HR (95% CI) P 
         
Any liver cancer     cases=182  cases=182  
  Any PPIs 40 208846 142 1949660 2.08 (1.46, 2.96) <0.001 1.99 (1.34, 2.94) <0.001 
  Omeprazole 24 122894 158 2035613 2.01 (1.31, 3.09) <0.001 1.78 (1.12, 2.83) 0.01 
  Lansoprazole 15 73849 167 2084658 2.01 (1.18, 3.42) 0.01 1.82 (1.05, 3.18) 0.03 
         
  Any H2RAs 8 39003 174 2119503 2.26 (1.11, 4.59) 0.02 1.70 (0.82, 3.53) 0.16 
  Ranitidine  8 36319 174 2122188 2.45 (1.21, 4.98) 0.01 1.82 (0.87, 3.79) 0.11 
         
Hepatocellular carcinoma         
  Any PPIs 20 208846 68 1949660 2.13 (1.29, 3.51) <0.001 1.60 (0.91, 2.83) 0.11 
  Any H2RAs 5 39003 83 2119503 2.93 (1.19, 7.23) 0.02 1.24 (0.46, 3.37) 0.67 
         
Intrahepatic bile duct carcinoma         
  Any PPIs 17 208846 55 1949660 2.28 (1.32, 3.94) <0.001 3.12 (1.72, 5.68) <0.001 
  Any H2RAs 2 39003 70 2119503 1.41 (0.34, 5.73) 0.64 1.58 (0.38, 6.56) 0.53 
†Model contains age at baseline, gender, deprivation, BMI, alcohol, smoking, comorbidities at baseline (including GORD, peptic ulcer disease, cirrhosis, hepatitis 
and diabetes) and other medication use at baseline (statins, aspirin). 
  
 Table 5. Sensitivity analysis for the association between PPI and H2RA use and risk of liver cancer in UK Biobank. 
 
Users  Non-users  Unadjusted   Adjusted† 
Cases P-years Cases P-years HR (95% CI) P HR (95% CI) P 
         
Any liver cancer         
  PPIs (main) 40 208846 142 1949660 2.08 (1.46, 2.96) <0.001 1.99 (1.34, 2.94) <0.001 
  PPIs (adjusting for H2RAs‡) 40 208846 142 1949660 2.08 (1.46, 2.96) <0.001 2.33 (1.58, 3.42) <0.001 
  PPIs (2 year lag) 31 162986 120 1525719 1.89 (1.27, 2.81) <0.001 1.79 (1.15, 2.77) 0.01 
  PPIs (4 year lag) 12 73143 65 689489 1.28 (0.69, 2.39) 0.43 1.30 (0.66, 2.55) 0.45 
         
  H2RAs (main) 8 39003 174 2119503 2.26 (1.11, 4.59) 0.02 1.70 (0.82, 3.53) 0.16 
  H2RAs  (adjusting for PPIs‡) 8 39003 174 2119503 2.26 (1.11, 4.59) 0.02 2.10 (1.03, 4.31) 0.04 
  H2RAs (2 year lag) 8 30557 143 1658149 2.73 (1.34, 5.57) 0.01 2.02 (0.96, 4.25) 0.06 
  H2RAs(4 year lag) 4 13984 73 748647 2.60 (0.95, 7.11) 0.06 2.26 (0.80, 6.39) 0.12 
         
Hepatocellular carcinoma         
  PPIs (main) 20 208846 68 1949660 2.13 (1.29, 3.51) <0.001 1.60 (0.91, 2.83) 0.11 
  PPIs (adjusting for H2RAs‡) 20 208846 68 1949660 2.13 (1.29, 3.51) <0.001 2.06 (1.18, 3.58) 0.01 
  PPIs (2 year lag) 18 162986 59 1525719 2.19 (1.29, 3.73) <0.001 1.62 (0.89, 2.94) 0.11 
         
  Any H2RAs (main) 5 39003 83 2119503 2.93 (1.19, 7.23) 0.02 1.24 (0.46, 3.37) 0.67 
  Any H2RAs  (adjusting for PPIs‡) 5 39003 83 2119503 2.93 (1.19, 7.23) 0.02 2.34 (0.94, 5.86) 0.07 
  Any H2RAs (2 year lag) 5 30557 72 1658149 3.36 (1.36, 8.32) 0.01 1.45 (0.53, 4.00) 0.47 
         
Intrahepatic bile duct carcinoma         
  PPIs (main) 17 208846 55 1949660 2.28 (1.32, 3.94) <0.001 3.12 (1.72, 5.68) <0.001 
  PPIs (adjusting for H2RAs‡) 17 208846 55 1949660 2.28 (1.32, 3.94) <0.001 3.11 (1.71, 5.66) <0.001 
  PPIs (2 year lag) 11 162986 44 1525719 1.82 (0.94, 3.54) 0.08 2.63 (1.28, 5.40) 0.01 
         
  Any H2RAs (main) 2 39003 70 2119503 1.41 (0.34, 5.73) 0.64 1.58 (0.38, 6.56) 0.53 
  Any H2RAs  (adjusting for PPIs‡) 2 39003 70 2119503 1.41 (0.34, 5.73) 0.64 1.59 (0.39, 6.54) 0.52 
  Any H2RAs (2 year lag) 2 30557 53 1658149 1.85 (0.45, 7.58) 0.39 2.20 (0.52, 9.28) 0.28 
†Model contains age at baseline, gender, deprivation, BMI, alcohol, smoking, comorbidities at baseline (including GORD, peptic ulcer disease, cirrhosis, hepatitis 
and diabetes) and other medication use at baseline (statins, aspirin). 
‡ Same model as † but additionally containing PPIs and H2RAs.
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